- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02901236
Bevacizumab Versus Mitomycin C as Trabeculectomy Adjuvant in Uncontrolled Glaucoma (AvastinvsMMC)
Bevacizumab Versus Mitomycin C as Trabeculectomy Adjuvant in Uncontrolled Glaucoma: A Randomized Pilot Trial.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, parallel, randomized, comparative, interventional feasibility study. Eyes of Caucasian patients with medically uncontrolled glaucoma or intolerance to glaucoma medications, who are evaluated at the glaucoma service of the Athens Vision Eye Institute and are scheduled for filtration surgery within one calendar year, are enrolled. If both eyes of one patient are eligible one eye is randomly selected. Inclusion criteria include adult patients with primary or secondary open angle or angle closure glaucoma with preoperative intraocular pressure (IOP) > 21 mmHg on maximally tolerated medical therapy at least on 2 occasions prior to randomization with the ability to attend regular follow-up. Exclusion criteria include age (< 18 years), pregnancy, severe ocular surface disease, need for combined phacotrabeculectomy, uveitic or neovascular glaucoma, any prior intraocular surgery except for uncomplicated phacoemulsification and a history of a systemic thromboembolic event within 6 months before surgery. The research adheres to the tenets of the Declaration of Helsinki and is approved by the Human Research Ethics Committee of the Athens Vision Eye Institute. Informed consent will be granted from all patients preoperatively explaining indications and risks of the procedure.
All patients are recruited by the principal investigator and surgeon (GK). The study is unblinded to both patients and investigators. Eyes are randomly assigned to 2 treatment arms by an online random number generator (www.random.org): the "mitomycin C group" that undergoes standard guarded trabeculectomy supplemented with mitomycin C (Kyowa, Galabank Business Park, UK); the "bevacizumab group" that undergoes guarded trabeculectomy with a single 1.25 mg intracameral injection of bevacizumab (Roche, Welwyn Garden City, UK). The online random number generator is accessed for each individual patient by the nursing staff (circulating nurse), which is unaware of study design and patient's characteristics, immediately prior to the surgical procedure. Sample size analysis (www.powerandsamplesize.com) reveals that for a power of 80% assuming a 5% type I error, an average post-op intraocular pressure of 12mmHg and a similar sampling ratio, 13 eyes in each group are necessary to detect a 3mmHg difference in IOP at twelve months (superiority or non-inferiority design). Assuming a dropout rate of 30% at 5 years the investigators aim for 20 eyes in each study group. Furthermore, power analysis reveals that for a power of 80% assuming a 5% type I error, a surgical success rate of 90% at 1 year and a similar sampling ratio, 20 eyes in each group are necessary to detect a 24% difference in rate of surgical success at twelve months (superiority or non-inferiority design).
Before surgery, all patients undergo a comprehensive eye examination including slit lamp biomicroscopy, best corrected visual acuity (BCVA) determination, intraocular pressure measurement using Goldmann applanation tonometry (GAT) at least on 2 separate occasions performed one week apart, gonioscopy and dilated fundus examination. All patients should have at least one visual field test on file, performed not more than 6 months prior to randomization. The Humphrey Visual Field Analyzer (HFA II-i, Carl Zeiss Meditec Inc, Dublin, CA, USA) will be used and the 24/2 SITA-Standard protocol will be utilized in all instances. Preoperative data collected from the medical record of individual patients include age, race, sex, diagnosis, study eye, BCVA, number and type of glaucoma medications, intraocular pressure, global visual field indices, central corneal thickness (CCT), cup to disc ratio, number and type of previous intraocular surgeries and previous glaucoma laser procedures. All pseudophakic eyes should have a history of primary open angle or exfoliation glaucoma, and should have undergone uneventful cataract extraction with a posterior chamber intraocular lens implantation.
Patients are examined on post-operative day one, day three, week one and every week thereafter for the first month, and subsequently on post-operative months 1, 3, 6, 9, and 12. A window of + 1 week is allowed for the 1st and 3rd month post-operative visits, and a window of + 2 weeks is allowed for the 6th, 9th and 12th month post-operative visits. During each visit a comprehensive ophthalmic examination is carried out. This includes intraocular pressure measurement, glaucoma medication requirement update, BCVA, review of early and late complications related to surgery (i.e., blebitis, bleb leak) and additional surgical interventions. These data are recorded in the patients' medical record and are extracted and tabulated in Excel 2013 spreadsheets (Microsoft, Redmond, WA) by an individual who is not participating in patient's management decisions and is blinded with respect to treatment assignment. Subsequently, data are analyzed by a separate individual who reveals study group assignment and calculates means, surgical success rates and complication rates. All patients' data are dealt with confidentiality. Statistical comparisons are performed according to initial treatment group assignment (intention to treat analysis).
Additional post-operative visits and/or interventions at the slit lamp such as 5-fluorouracil (5-FU) injections, bleb needlings and laser suture lyses are at the discretion of the treating ophthalmologist and do not qualify as failures. BCVA is recorded by certified optometrists utilizing clear chart digital screens (Reichert, Depew, NY, USA) placed at 4 m. All patients will undergo 24/2 Swedish Interactive Threshold Algorithm (SITA) Standard Automated Perimetry (SAP) on an annual basis in the post-operative period. SAP will be repeated typically within one month if unreliable.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- adult patients
- primary or secondary open angle or angle closure glaucoma
- preoperative intraocular pressure > 21 mmHg on maximally tolerated medical therapy at least on 2 occasions prior to randomization
- ability to attend regular follow-up
Exclusion Criteria:
- age (< 18 years)
- pregnancy
- severe ocular surface disease
- need for combined phacotrabeculectomy
- uveitic or neovascular glaucoma
- any prior intraocular surgery except for uncomplicated phacoemulsification
- a history of a systemic thromboembolic event within 6 months before surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Mitomycin C
Standard Guarded Trabeculectomy will be performed.
In this arm 0.02% of mitomycin C (Kyowa, Japan) will be applied on bare sclera under the conjunctiva for 2 minutes.
Subsequently, the area will be copiously irrigated with balanced salt solution.
|
A fornix based conjunctival peritomy is performed.
A partial thickness scleral flap is dissected.
Then trabeculectomy is performed with a Kelly's punch.
A surgical iridectomy is performed.
The scleral flap is secured with two pre-placed 8-0 Vicryl sutures (Ethicon, Somerville, NJ).
The anterior chamber (AC) is inflated with balanced salt solution and suture tension is adjusted.
Finally, conjunctiva is closed with 10-0 running Nylon sutures (Ethicon, Somerville, NJ).
Patients receive a subconjunctival injection of 0.4 ml dexamethasone (4 mg/ml) and of 0.4 ml gentamicin (40 mg/ml) at the end of the case.
Adjuvant pharmacologic treatment to prevent episcleral fibrosis and failure of the procedure is applied according to treatment arm assignment.
Other Names:
Sponges soaked in 0.02% mitomycin C (MMC) will be applied on bare sclera for 2 minutes.
Subsequently, the area will be copiously irrigated with balanced salt solution.
Other Names:
|
Active Comparator: Bevacizumab
Standard Guarded Trabeculectomy will be performed.
In this arm at the end of the case and after conjunctival closure 1.25mg of bevacizumab (Avastin; Genentech, San Francisco, CA) will be injected into the the anterior chamber through a paracentesis.
|
A fornix based conjunctival peritomy is performed.
A partial thickness scleral flap is dissected.
Then trabeculectomy is performed with a Kelly's punch.
A surgical iridectomy is performed.
The scleral flap is secured with two pre-placed 8-0 Vicryl sutures (Ethicon, Somerville, NJ).
The anterior chamber (AC) is inflated with balanced salt solution and suture tension is adjusted.
Finally, conjunctiva is closed with 10-0 running Nylon sutures (Ethicon, Somerville, NJ).
Patients receive a subconjunctival injection of 0.4 ml dexamethasone (4 mg/ml) and of 0.4 ml gentamicin (40 mg/ml) at the end of the case.
Adjuvant pharmacologic treatment to prevent episcleral fibrosis and failure of the procedure is applied according to treatment arm assignment.
Other Names:
After conjunctival closure 1.25mg of bevacizumab will be injected into the anterior chamber through a paracentesis created earlier during the case.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intraocular Pressure
Time Frame: 1 year after the intervention
|
Intraocular pressure measured by Goldmann applanation tonometry was declared the primary outcome measure
|
1 year after the intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Surgical Success (Survival of Surgical Procedure)
Time Frame: 1 year after the intervention
|
Tube Versus Trabeculectomy (TVT) study criteria are used to define complete surgical success (i.e., intraocular pressure > 5 mmHg and < 21 mmHg in conjunction with at least 20% reduction in intraocular pressure without medications, no re-operation for glaucoma and maintained light perception).26
Qualified success referred to success with glaucoma medications.
|
1 year after the intervention
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gerassimos Kopsinis, M.D., Ph.D., Athens Vision Eye Institute
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Eye Diseases
- Ocular Hypertension
- Glaucoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antineoplastic Agents
- Alkylating Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Antibiotics, Antineoplastic
- Bevacizumab
- Mitomycins
- Mitomycin
- Antimetabolites
Other Study ID Numbers
- Gl001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glaucoma
-
Imperial College Healthcare NHS TrustIRIDEX CorporationNot yet recruitingGlaucoma | Glaucoma, Open-Angle | Glaucoma, Angle-Closure | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma Secondary | Glaucoma Traumatic | Glaucoma Uveitic
-
Wills EyeIOP OphthalmicsTerminatedPrimary Open Angle Glaucoma | Neovascular Glaucoma | Uveitic Glaucoma | Pseudoexfoliation Glaucoma | Primary Angle Closure Glaucoma | Pigmentary Glaucoma | Traumatic GlaucomaUnited States
-
Centre hospitalier de l'Université de Montréal...CompletedGlaucoma | Glaucoma, Open-Angle | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma and Ocular Hypertension | Glaucoma, Uncompensated | Glaucoma SecondaryCanada
-
Pro Top & Mediking Company LimitedCompletedOpen Angle Glaucoma | Neovascular Glaucoma | Angle Closure Glaucoma | Uveitis Glaucoma | Young Age Glaucoma | High Risk PatientEstonia
-
Sanoculis LtdCompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaIsrael
-
Bausch & Lomb IncorporatedNicOx Inc.CompletedPrimary Open Angle Glaucoma | Ocular Hypertension | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaUnited States
-
Sensimed AGCompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaFrance
-
iSTAR MedicalInternational Drug Development InstituteActive, not recruitingGlaucoma, Open-Angle Glaucoma EyeIndia, Panama
-
Dr. Kaweh MansouriEnrolling by invitationGlaucoma, Angle-Closure | Surgery | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma; Drugs | Glaucoma, Pigmentary | Glaucoma Secondary | Glaucoma Open-Angle | Glaucoma Congenital | Glaucoma CapsulareSwitzerland
-
Ivantis, Inc.CompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaUnited States
Clinical Trials on Standard Guarded Trabeculectomy
-
University of California, San FranciscoSeva Foundation; Lumbini Eye Institute and HospitalUnknown
-
Sunnybrook Health Sciences CentreCompletedGlaucoma | Corneal Endothelial Cell LossCanada
-
Shanghai Eye Disease Prevention and Treatment CenterUnknown
-
University of OklahomaCompletedPrimary Open Angle Glaucoma | Cataract | Pigmentary GlaucomaUnited States
-
University of ZurichCompleted
-
Assiut UniversityUnknownGlaucoma | Angle Closure Glaucoma | Cataract SecondaryEgypt
-
Queen's UniversityGlaucoma Research & Education GroupWithdrawn
-
Helsinki University Central HospitalRecruitingNormal Tension GlaucomaFinland